Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elisa Oquendo

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Bioanalysis|April 23, 2021
Critical reagent generation, characterization, handling and storage workflows: impact on ligand binding assaysElisa Oquendo, Jolaine Savoie, Joyce M Swenson, et al.
Bioanalysis|March 26, 2021
Using multiple platforms for critical reagents selection process to support pharmacokinetic ligand-binding assay developmentElisa Oquendo, Xu Lin, Sally Ye, et al.
Advanced Drug Delivery Reviews|July 24, 2008
Monitoring oxidative and nitrative modification of cellular proteins; a paradigm for identifying key disease related markers of oxidative stressJames Murray, C Elisa Oquendo, John H Willis, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|August 29, 2014
A systematic assessment of mitochondrial function identified novel signatures for drug-induced mitochondrial disruption in cellsNianyu Li, Elisa Oquendo, Roderick A Capaldi, et al.
Cancer Cell|December 9, 2008
HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinomaJohn D Gordan, Priti Lal, Vijay R Dondeti, et al.
Oncoimmunology|June 27, 2022
Combination of two novel blocking antibodies, anti-PD-1 antibody ezabenlimab (BI 754091) and anti-LAG-3 antibody BI 754111, leads to increased immune cell responsesMarkus Zettl, Melanie Wurm, Otmar Schaaf, et al.
Frontiers in Immunology|June 6, 2025
Immunogenicity risk assessment for tailored mitigation and monitoring of biotherapeutics during development: recommendations from the European Immunogenicity PlatformJoanna Grudzinska-Goebel, Karin Benstein, Karien Bloem, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Bioanalysis|April 23, 2021
Critical reagent generation, characterization, handling and storage workflows: impact on ligand binding assaysElisa Oquendo, Jolaine Savoie, Joyce M Swenson, et al.
Bioanalysis|March 26, 2021
Using multiple platforms for critical reagents selection process to support pharmacokinetic ligand-binding assay developmentElisa Oquendo, Xu Lin, Sally Ye, et al.
Advanced Drug Delivery Reviews|July 24, 2008
Monitoring oxidative and nitrative modification of cellular proteins; a paradigm for identifying key disease related markers of oxidative stressJames Murray, C Elisa Oquendo, John H Willis, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|August 29, 2014
A systematic assessment of mitochondrial function identified novel signatures for drug-induced mitochondrial disruption in cellsNianyu Li, Elisa Oquendo, Roderick A Capaldi, et al.
Cancer Cell|December 9, 2008
HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinomaJohn D Gordan, Priti Lal, Vijay R Dondeti, et al.
Oncoimmunology|June 27, 2022
Combination of two novel blocking antibodies, anti-PD-1 antibody ezabenlimab (BI 754091) and anti-LAG-3 antibody BI 754111, leads to increased immune cell responsesMarkus Zettl, Melanie Wurm, Otmar Schaaf, et al.
Frontiers in Immunology|June 6, 2025
Immunogenicity risk assessment for tailored mitigation and monitoring of biotherapeutics during development: recommendations from the European Immunogenicity PlatformJoanna Grudzinska-Goebel, Karin Benstein, Karien Bloem, et al.
Pageof 1